EMROSI

Growth

minocycline hydrochloride extended-release

Journey Medical
NDAORALCAPSULE, EXTENDED RELEASE
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
0/100

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of EMROSI for the treatment of rosacea is unknown. 12.2 Pharmacodynamics The pharmacodynamics of EMROSI for the treatment of rosacea are unknown. 12.3 Pharmacokinetics EMROSI is not bioequivalent to any other minocycline products. The…

Indications (5)

inflammatory lesions (papulespustules) of rosacea in adultsdevelopment of drug-resistant bacteriause EMROSI onlyto maintain the effectiveness of other antibacterial drugs

Loss of Exclusivity

LOE Date
Jan 7, 2039
156 months away
Patent Expiry
Jan 7, 2039
Exclusivity Expiry
Nov 1, 2027

Patent Records (3)

Patent #ExpiryTypeUse Code
10905664
Jan 7, 2039
U-4043
11191740
Jan 7, 2039
U-4043
11364212
Jan 7, 2039
U-4043
Company
Journey Medical
Journey Medical
AZ - Scottsdale
1 open job
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers